Landos Biopharma (LABP) Stock Price, News & Analysis

Company Overview

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Key Stats

• Today's Range: $22.75 to $22.94
• 50-Day Range: $21.51 to $22.93
• 52-Week Range: $2.50 to $22.94
• Volume: 50,800 shs
• Average Volume: 19,700 shs
• Market Capitalization: $71.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.42
• Consensus Rating: Hold

LABP Stock Analysis - Frequently Asked Questions

How were Landos Biopharma's earnings last quarter?

Landos Biopharma, Inc. (NASDAQ:LABP) posted its earnings results on Friday, May, 12th. The company reported ($0.90) earnings per share for the quarter, topping analysts' consensus estimates of ($1.00) by $0.10.

When did Landos Biopharma's stock split?

Landos Biopharma's stock reverse split on Friday, May 26th 2023. The 1-10 reverse split was announced on Friday, May 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Landos Biopharma IPO?

Landos Biopharma (LABP) raised $101 million in an initial public offering on Thursday, February 4th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and SVB Leerink acted as the underwriters for the IPO and Raymond James was co-manager.

What other stocks do shareholders of Landos Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Landos Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), e.l.f. Beauty (ELF), Jabil (JBL) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/12/2023
• Today: 3/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:LABP
• CIK: 1785345
• Web: landosbiopharma.com
• Phone: 540-218-2232
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.42
• High Stock Price Target: $20.42
• Low Stock Price Target: $20.42
• Potential Upside/Downside: -10.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,930,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -73.00%
• Return on Assets: -63.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.43
• Quick Ratio: 4.43

Sales & Book Value

• Annual Sales: $18 million
• Price / Sales: 3.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.41 per share
• Price / Book: 3.09

Miscellaneous

• Outstanding Shares: 3,130,000
• Free Float: 3,085,000
• Market Cap: $71.77 million
• Optionable: Not Optionable
• Beta: 0.14